Belgium· BE-AMP-SAM599253-00
Nucala 40 mg
A mepolizumab product containing mepolizumab, registered in Belgium by GlaxoSmithKline Trading Services. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Mepolizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC R03DX09 (mepolizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Mepolizumab · ATC R03DX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Mepolizumab
- Manufacturer
- GlaxoSmithKline Trading Services
- Country
- Belgium (BE)
- ATC code
- R03DX09
- ATC class
- Mepolizumab
- Defined daily dose
- 3.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb4513974EUR 450.96
- be_apb7735756
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- SpainNUCALA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAGlaxosmithkline Trading Services Limited
- IcelandNucalaGlaxoSmithKline Trading Services Limited
- NorwayNucalaGlaxoSmithKline Trading Services Limited
- PolandNucalaGlaxoSmithKline Trading Services Limited
- SwedenNucala 40 mg Injektionsvätska, lösning i förfylld sprutaGlaxoSmithKline Trading Services Ltd
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5cd6202e-af06-48a2-8126-5f0423eb059c GET /v1/drugs/5cd6202e-af06-48a2-8126-5f0423eb059c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Nucala 40 mg",
"name_fr": "Nucala 40 mg",
"name_nl": "Nucala 40 mg",
"amp_code": "SAM599253-00",
"strengths": [
"100.0000"
],
"pack_count": 2,
"substances": [
"Mepolizumab",
"Disodium Edetate",
"Disodium Hydrogen Phosphate Heptahydrate",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Mepolizumab",
"authorisation_numbers": [
"EU/1/15/1043/010",
"EU/1/15/1043/009"
]
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.